Description
SignalGen is a generative‑AI platform developed by Los Alamos National Laboratory that predicts the optimal signal peptide for a given protein, organism, and target cellular compartment. The technology enables biotech, pharmaceutical, and synthetic‑biology companies to improve protein expression yields and streamline development cycles. Licensing is offered on a non‑exclusive or exclusive basis, with no external development services requested.
• AI‑driven prediction of signal peptides for any protein (human or non‑human)
• Considers protein sequence, desired subcellular location, and organism
• Natural‑language interface eliminates need for coding
• Demonstrated ~90 % prediction accuracy (TRL 3)
• Applicable to therapeutic protein development, vaccines, drug discovery, biomanufacturing, protein engineering, synthetic biology, industrial biotech, and basic molecular‑biology research
• Patent‑pending technology (U.S. Patent pending, LA‑UR‑26‑27860)
• Licensing contacts through LANL’s Technology Transfer office
Attached files
Contact
Satya Srinivasan